Supporting information

S1 Fig. Effect of baseline HCV-RNA prevalence and differential duration of scale-up campaign (10, 20 and 30 years). Based on scale-up of 10 infection per 1000 PWID with a high proportion of cured infection (SVR 90%), a 12-week treatment duration, and no acquired immunity ($\xi=0$)

![Bar chart showing HCV RNA prevalence changes over different durations and baseline prevalences.](chart.png)